Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde, with an ambitious plan to create a new class of drugs based on Endless RNA.

NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Lifesciences in a deal that will provide additional cash for its main drug candidate ...

CCM Biosciences’ novel, orally bioavailable FLT3 inhibitors (CCM-405 and CCM-445) are the first drug candidates to overcome both FLT3-ITD juxtamembrane domain and tyrosine kinase domain (TKD ...

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung ...

Cimzia (certolizumab pegol) is a prescription injection that treats Crohn’s disease, arthritis, and other conditions. Learn about side effects, dosage, and more.

Registration Fee Expense: 0.0006 % Expense Waiver: 0.0291 % Total Expense: 0.2015 % Shareholder Reporting Fee Expense: 0.0002 % Transfer Agency Fee Expense ...

Sidebar Executive Summary. Mechanism of action. TMC207 is a first-in-class anti-TB diarylquinoline (also named R207910 or the 'J' compound) with activity against drug-sensitive and drug-resistant TB.

EARNEST PARTNERS SMID CAP CORE FUND 1 CLASS- Performance charts including intraday, historical charts and prices and keydata.